參考資料 :

1. Mercilon Prescribing Information. Organon Hong Kong. 2021.
2. Lammers P and Op Ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinylestradiol. Acta Obstet Gynecol Scand. 1991;70:497-500.
3. WHO Family planning- A global handbook for providers. 2022 Edition. Available from: https://www.who.int/publications/i/item/9780999203705. [Accessed 3 Nov 2023].
4. Marvelon Prescribing Information. Organon Hong Kong. 2021.
5. Bilotta P & Favilli S. Clinical Evaluation of a Monophasic Ethinylestradiol/ Desogestrel-containing Oral Contraceptive. Arzneim. Forsch. 1988;38(II)7:932-4.
6. Data on file.
7. Teal S & Edelman A. Contraception Selection, Effectiveness, and Adverse Effects. JAMA. 2021 ;326(24):2507-8.
8. Yang M & Li Z. The development history of oral contraceptives. Zhonghua Yi Shi Za Zhi. 2021;51(2):92-6.
9. American College of Obstetricians and Gynecologists. Emergency Contraception. Available from: https://www.acog.org/womens-health/faqs/emergency-contraception. [Accessed 3 Nov 2023].
10. European Medical Agency. https://www.ema.europa.eu.psusa.desogestrel. [Accessed 27 Apr 2023].